Abstract: Amorphous forms of onapristone and methods of making such amorphous forms are provided. Amorphous forms can be characterized by their X-ray powder diffraction patterns and other properties.

Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.

Abstract: The subject invention pertains to materials and methods for the prevention and treatment of disease conditions associated with oxidative stress or a compromised reducing environment, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Another aspect of the subject invention concerns compositions formulated for administration as an enema. In one embodiment, a composition suitable for administration as an enema comprises an effective amount of 5-ASA and a steroid such as budesonide or hydrocortisone. The subject invention also concerns compositions formulated for oral administration. In one embodiment, a composition comprises alpha-lipoic acid, and/or N-acetyl-L-cysteine (N-A-C), and/or L-glutamine. The alpha-lipoic acid can be racemic alpha-lipoic acid, R-lipoic acid, or R-dihydro-lipoic acid. Methods of the invention include administration of compounds or compositions of the invention.

Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.

Abstract: A topically applicable chemical peel composition for home use having from about 4% to about 13%, by weight, of alpha hydroxy acid, from about 0.1% to about 2.0%, by weight, of salicylic acid, from about 0.1% to about 2.0%, by weight, of phenylethyl resorcinol and balance essentially dermatologically acceptable liquid solvent. In addition, a chemical skin peel regime or regimen including topical application onto the skin is also disclosed.

Abstract: The disclosure provides controlled release compositions comprising tetracyclines and in some embodiments, doxycycline. The controlled release doxycycline compositions of the invention exhibit a superior dissolution profile and provide reduced side effects such as nausea and irritation.

Abstract: The invention relates to a topical suspension formulation that includes a tetracycline, a liquid medium and a polymeric gelling agent. The tetracycline may be in the form of its pharmaceutically acceptable salts, hydrates, or polymorphs and is in a suspended form within the formulation. The liquid medium is selected such that it does not dissolve or substantially minimally dissolves the tetracycline. The gelling agent is a polymeric hydrocarbon gelling agent. Preferably, the tetracycline has a particle size of less than or equal to about 20 microns.

Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, such as zoledronic acid in an acid or a salt form, or in a molecular complex can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.

Abstract: Oral capsules have been dismissed as a dosage form for delivery high dosages of krill phospholipids, but by purifying these to high levels it is indeed possible to use this dosage form to deliver, for example, 700 mg or more phospholipids per capsule.

Abstract: Current krill oil extracts are liquid at room temperature and include only about 45-55% phospholipids. As the purity of phospholipids increases, the extracts become more viscous, making them difficult to handle and process. The invention mixes these pure materials with viscosity-reducing agents to make them amenable to processes such as encapsulation. Thus the invention retains the useful liquid characteristics of known krill extracts while providing much higher concentrations of phospholipids.

Abstract: The invention generally relates to anti-aging compositions and methods for using the anti-aging compositions. In one aspect, the invention provides a method for preventing cellular aging in a cell of a subject, the method comprising the step of providing to the cell an effective amount of at least one lithium compound or a pharmaceutically acceptable salt thereof, and an effective amount of at least one glycyrrhizie triterpenoid compound or a pharmaceutically acceptable salt thereof, thereby preventing the cell from aging. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: The present invention provides methods of treating various disorders associated with mitochondrial dysfunction, including but not limited to metabolic disorders, neurodegenerative diseases, chronic inflammatory diseases, and diseases of aging.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of acute exacerbation of chronic obstructive pulmonary disease. In particular, the present invention relates to a method of treating acute exacerbation of chronic obstructive pulmonary disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one NKT cell agonist.

Abstract: A new class of pseudo-trisaccharide aminoglycosides having an alkyl group at the 5? position, exhibiting efficient stop codon mutation readthrough activity, low cytotoxicity and high selectivity towards eukaryotic translation systems are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders, as well as processes of preparing these aminoglycosides. The disclosed aminoglycosides can be represented by the general formula I: or a pharmaceutically acceptable salt thereof, wherein R1 is selected from the group consisting of alkyl, cycloalkyl and aryl; and all other variables and features are as described in the specification.

Abstract: The invention provides a method of treating heterotopic ossification in a subject in need thereof. The method comprises administering a hypoxia inducible factor-1? (Hif-1?) inhibitor to the subject. In various embodiments, the Hif-1? inhibitor is PX-478, rapamycin, or digoxin.

Abstract: A biocompatible scaffold is provided that includes a biocompatible scaffold substrate and an amount of a demethylation agent or a methylation inhibitor, in an amount effective to induce and/or promote tissue repair and regeneration. The demethylation agent or methylation inhibitor can be a cytidine analog. The scaffold can further include an effective amount of one or more of a target specific growth factor, a cytokine, a signaling molecule or a pharmaceutically acceptable carrier. The scaffold can be constructed of a natural or non-natural material; one alternative is a gel formed by the catalytic activity of transglutaminase.

Abstract: The present invention is directed to (the use of) a solution containing at least one nucleic acid (sequence) and free mannose for lyophilization, transfection and/or injection, particularly of RNA and mRNA. The inventive solution exhibits a positive effect on stabilization of the nucleic acid (sequence) during lyophilization and storage but also leads to a considerable increase of the transfection efficiency of a nucleic acid. It thus also increases in vivo expression of a protein encoded by such a nucleic acid upon increased transfection rate. The present invention is furthermore directed to a method of lyophilization using the mannose-containing solution, to pharmaceutical compositions, vaccines, kits, first and second medical uses applying such a mannose-containing solution and/or a nucleic acid (sequence) lyophilized or resuspended with such a solution.

Abstract: Provided herein are gapmer oligomeric compounds for reduction of target RNA in vivo comprising different nucleotide modifications within one or both wing regions. Also provided are methods of using such oligomeric compounds, including use in animals. In certain embodiments, such compound have desirable potency and toxicity characteristics.

Abstract: The present invention provides the use of the gene or protein of adenylate kinase 6 (AK6) or the combination of AK6 and other 14 genes or proteins related to male infertility for (i) preparing the agent or kit for detecting male infertility; and/or (ii) preparing the pharmaceutical composition for contraception.

Abstract: Disclosed herein are antisense compounds and methods for decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) or Lp(a). Certain diseases, disorders or conditions related to apo(a) or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The antisense compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.

Abstract: Provided are a therapeutic agent and a prophylactic agent for keratoconjunctive disorder, each agent comprising sacran. A therapeutic agent or a prophylactic agent for keratoconjunctive disorder, each agent comprising sacran.

Abstract: Compositions are described that contain treated chitosan, modified chitosan and/or modified and treated chitosan for use in formulations for skin, hair and nails, and in compositions and methods of reducing topical agent-induced skin irritation and inflammation.

Abstract: Main chain polyamines comprise amine and ammonium groups along the polymer backbone. Main chain polyamines can be used as pharmaceutical agents and in pharmaceutical compositions. The main chain polyamines are particularly useful in the treatment or prevention of mucositis and infection, specifically oral mucositis and surgical site infection.

Abstract: A method of providing a therapeutic composition includes administering a ROS reducing drug, calcium channel blocker, anti-fibrotic, anti-inflammatory, or anti-hypertensive drug and administering inhaled nitric oxide and reducing symptoms of oxidative stress and/or fibrosis in a patient.

Abstract: A method of administration of a thiol-based chemoprotectant agent including NAC (N-acetylcysteine) and STS (sodium thiosulfate) that markedly affects biodistribution and protects against injury from diagnostic or therapeutic intra-arterial procedures. A method for treating or mitigating the side effects of cytotoxic cancer therapy for tumors located in the head or neck and brain tumors. The thiol-based chemoprotectant agent is administered intra-arterially with rapid and first pass uptake in organs and tissues other than the liver.

Abstract: The present invention is generally directed to an oral pharmaceutical composition comprising a sulfate salt, for example, sodium sulfate and/or potassium sulfate, wherein the composition is substantially free of magnesium sulfate. The present invention is further directed to use of such oral pharmaceutical compositions to induce laxation or to treat or prevent constipation, e.g., opioid-induced constipation.

Abstract: Methods are provided to make clinoptilolite into a water-soluble hydrolyzed form suitable for various administration routes, including oral administration. Absorption of water-soluble hydrolyzed clinoptilolite fragments can aid in detoxification by binding heavy metals and environmental toxins, can reduce reactive oxygen species and inflammation related to heavy metals and other/environmental toxins, resulting in an increase in energy, and/or in an increase in one or more of focus, concentration, and memory. Water-soluble hydrolyzed clinoptilolite fragments can be combined with one or more dietary supplements, including various vitamins and sleep aids.

Abstract: The present invention relates to a multicomponent oral health care composition, comprising a source of a fluoride ion, and a source of a calcium ion, a source of a phosphate ion, and stabilised chlorine dioxide, that can be used as a toothpaste, oral spray or a mouth wash/oral rinse formulation. The different components in the composition act synergistically together to clean the teeth and mucous membranes of an oral cavity of a subject, perfuming them or protecting them in order to keep them in good condition, change their appearance or correct unpleasant odours. They achieve this by inhibiting caries, promoting teeth remineralisation, and helping to alleviate dentine hypersensitivity, gingivitis and periodontal disease.

Abstract: Disclosed are pharmaceutical compositions and related methods for treating a subject with a viral or retroviral infection. The disclosed compositions and methods comprise and utilize an effective amount of one or more vanadium-containing compounds and an effective amount of one or more sulfonylureas. In certain embodiments, the viral infection is human immunodeficiency virus (HIV) and the compositions and methods improve one or more immunologic cellular parameters, such as viral load, CD4 counts and CD4/CD8 lymphocyte cell ratios in a subject. Also disclosed are methods of improving one or more immunologic cellular parameters that are associated with viral infections such as HIV in a subject, including viral load, CD4 counts and CD4/CD8 lymphocyte cell ratios.

Abstract: This document relates to bi-carbonate-buffered dialysis solutions with physiological phosphate content and increased stability. The solutions include an organic ester of phosphoric acid, calcium ions and/or magnesium ions, and optionally additional electrolytes, buffers and glucose in physiologically effective concentrations.

Abstract: Embodiments of the methods and compositions provided herein relate to inducing hair growth in a subject. Some embodiments include screening for agents to modulate hair growth.

Abstract: The invention is directed to methods and compositions for cell-based targeted delivery of predetermined compounds to a population of target cells. In some embodiments, methods of the invention include providing cytotoxic lymphocytes genetically modified to produce and sequester in lytic granules fusion proteins comprising a granzyme, or other effector agent, and a predetermined protein, so that upon specific contact of the cytotoxic lymphocytes with the target cells, the granzyme-perforin pathway of the cytotoxic lymphocytes is activated, leading to the delivery of the fusion protein to the cytosols of the target cells.

Abstract: The present application relates to a non-human mammal model of a human neurodegenerative disorder, methods of producing the non-human mammal model, and methods of using the non-human mammal model to identify agents suitable for treating a neurodegenerative disorder. The present application also relates to methods of treating neurodegenerative disorders and restoring normal brain interstitial potassium levels.

Abstract: The present application relates to a non-human mammal model of a human neurodegenerative disorder, methods of producing the non-human mammal model, and methods of using the non-human mammal model to identify agents suitable for treating a neurodegenerative disorder. The present application also relates to methods of treating neurodegenerative disorders and restoring normal brain interstitial potassium levels.

Abstract: Adult stem cells are reprogrammed to form pacemaker cells and Purkinje cells through the sequential activation of SHOX2>TBX5>HCN2. These Purkinje cells spontaneously surround and connect with the larger pacemaker cells, thus forming an induced sinoatrial body that produces funny current and can make cardiovascular tissues beat in a manner similar to a natural sinoatrial node.

Abstract: The invention is in the field of regenerative medicine. It has been found that the conditioned medium of non-oval pluripotent liver progenitor cells exerts a tissue regenerating effect. A preparation of the cell free conditioned medium is therefore useful in the treatment of injury and organ failure, preferably liver and/or injury or failure.

Abstract: Provided herein are novel Lactobacillus fermentum strains, NRRL B-67059 or NRRL B-67060, compositions containing the NRRL B-67059 or NRRL B-67060 strains, and fermented dairy products and bioactive compounds prepared using the NRRL B-67059 or NRRL B-67060 strains. Also provided are methods of modulating the immune system of a subject.

Abstract: Nutritional compositions that mimic whole foods and methods of using the nutritional compositions are provided. The nutritional compositions may include an increased number and variety of fruits and vegetables, an increased variety of macronutrient sources and an increased amount of other components that are found in whole foods. The nutritional compositions may also include ethnicity-specific meals and organic ingredients and provide emotional appeal to the patient and/or the patient's caregiver. Methods of administering such nutritional compositions to patients in need of same are also provided.

Abstract: A nutritional supplement includes a predetermined amount of an ATP increasing herbal component which includes species of cordyceps to increase a long-term internal ATP energy; a predetermined amount of L-theanine to increase a mental energy; and a predetermined amount of external energy stimulants including caffeine to provide a short-live external energy, which may be utilized as beverages, foods, supplements, and drugs so as to provide the absolute energy for all mammals including human beings, and pets such as dogs, cats, and rodents.

Abstract: The present invention relates to a composition containing a masterwort (Peucedanum Ostruthium) extract as an active ingredient. The composition of the present invention exhibits effects of reducing the amount of endothelin 1 by containing a masterwort extract, and reducing the overexpression of NK1R and EDN1 genes. Therefore, the masterwort extract of the present invention can exhibit, by said effects, skin homeostasis maintenance and anti-stress effects, and thus can be widely used as acomposition for maintaining skin homeostasis in the pharmaceutical or cosmetic field.

Abstract: The present invention relates to orodispersible films comprising a plant extract and to film forming suspensions comprising a plant extract. Further, the present invention relates to processes for preparing the orodispersible films and the film forming suspensions.

Abstract: The present invention relates to a composition for muscle function improvement or exercise ability enhancement, the composition including kirenol, a Siegesbeckia herba extract, or a fraction of the Siegesbeckia herba extract as an active ingredient. Kirenol, the Siegesbeckia herba extract containing kirenol, or the Siegesbeckia herba extract fraction according to the present invention has an excellent effect of increasing muscle mass by increasing the protein expression of p-mTOR, which is a major gene concerned with muscle functions. Also, kirenol, the Siegesbeckia herba extract containing kirenol, or the Siegesbeckia herba extract fraction according to the present invention has an effect of remarkably enhancing exercise ability by increasing the protein expression of PGC-1?, which is a major gene concerned with exercise ability. In addition, the present invention is a natural product, and thus is safe for use without side effects and can be used as a medicine or food.

Abstract: The extract of a mixture of cinnamon twig and moutan root bark, cinnamon twig and peony root, or cinnamon twig and poria according to the present invention has been confirmed to inhibit the excessive generation of advanced glycation end-products, which occurs under chronic diabetic conditions, exhibit the effect of fragmentizing a cross-link between the advanced glycation end-products and matrix proteins, have an excellent effect in inhibiting the generation of the advanced glycation end-products in a human retinal pigment epithelial cell line subjected to a hyperglycemic or aging environment, and have excellent effects in delaying, preventing, and treating diabetic complications, muscular degeneration, commotio retinae, and lower extremity edema in various animal models of diabetic complications, macular degeneration, and lower extremity edema, and thus the mixture extract can effectively be used as an active ingredient for a composition for preventing and treating diabetic complications, including diabetic

Abstract: Provided is a fermented food extract that has a blood pressure-lowering action and is useful as a functional health food or pharmaceutical composition. This fermented food extract is obtained by: subjecting a fermented food, preferably a fermented fagopyrum esculentum lyophilisate, to acetone extraction; eluting the fermented fagopyrum esculentum acetone extract using a solid phase extract cartridge filled with a resin to which a phenyl group is bonded, with formic acid-containing water used as an eluent; and fractionating and purifying the eluate using a column (PFP column) filled with a carrier to which a pentafluorophenyl group is bonded, with formic acid/methanol-containing water used as a mobile phase. This functional health food or pharmaceutical composition contains said extract or at least a part thereof as an active ingredient.

Abstract: An appetite-suppressing composition is characterized by comprising, as an active component, the liquid component derived from Indian mulberry (Morinda citrifolia). The solution is the liquid component extracted from fermented Indian mulberry fruits, which includes the residual liquid containing the >3,000 component and the filtrated liquid containing the <3,000 component. Considerably, provided is the food that possesses the appetite-suppressing composition without showing the non-specific effect on appetite suppression.

Abstract: An object of the present invention is to find a component that is safe and is capable of effectively exerting various effects such as prevention or amelioration of diabetes, prevention or amelioration of metabolic syndrome, amelioration of insulin resistance, inhibition of an increase in a postprandial blood sugar level, and inhibition of ?-glucosidase activity. The present invention provides agents for preventing or ameliorating diabetes or the like, the agents including a component of a hybrid plant of Camellia sinensis and Camellia taliensis as an active ingredient. The hybrid plant is preferably Sun Rouge, and each of the agents preferably includes a tea leaf extract of the hybrid plant.

Abstract: A composition of extracts from the genus Hippeastrum and their components is intended for the production of pharmaceuticals and dietary supplements. The composition consists of galanthamine from 40% to 98%, haemanthamine from 0.01% to 35%, narwedine from 0.01% to 10%, and/or other alkaloids of homolycorine-, and/or tazettine-, and/or monthanine- and/or haemanthamine- and/or galanthamine- and/or lycorine-type from 0.001% to 35%, and non-alkaloid plant metabolites from 0.001 to 1%, derived from the total extract of the genus Hippeastrum. The alkaloid content can vary from 0.01% to 99% and non-alkaloid plant metabolites and/or other inactive excipients and/or solvents from 1% to 99.9%, respectively. The composition may be in dry or liquid form. It is used to isolate pure compounds of haemanthamine and galanthamine.

Abstract: This invention relates to novel extracts from sugar cane and sugar beet molasses and the characterisation of those extracts. The extracts are enriched in hydrophobic compounds including polyphenols, in levels 5 to 10 fold higher than found in molasses itself. Methods for extracting the extract are also described, together with new uses for the extracts as food ingredients, food modifiers and therapeutic substances.

Abstract: The present invention relates to hydrogels comprising a plurality of amphiphilic peptides and/or peptoids capable of self-assembling into three-dimensional macromolecular nanofibrous networks, which entrap water and form said hydrogels, wherein at least a portion of said plurality of amphiphilic peptides and/or peptoids is chemically cross-linked. The present invention further relates to methods for preparing such hydrogels and to various uses of such hydrogels, e.g. as cell culture substrates, for drug and gene delivery, as wound dressing, as an implant, as an injectable agent that gels in situ, in pharmaceutical or cosmetic compositions, in regenerative medicine, in tissue engineering and tissue regeneration, or in electronic devices. It also relates to a method of tissue regeneration or tissue replacement using a hydrogel in accordance with the present invention.

Abstract: The invention relates to a use of an aurantiamide dipepetide derivative in the treatment or prevention of angiogenesis-related diseases. Accordingly, aurantiamide dipeptide derivatives can be used as angiogenesis inhibitor, whereby preventing or treating invasive and metastatic cancer and ocular neovascularization (particularly macular degeneration such as pathological neovascularization of age-related macular degeneration (AMD)).